Published in J Clin Invest on February 01, 1973
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Cell-mediated immune response of ragweed-sensitive patients to ragweed antigen E. In vitro lymphocyte transformation and elaboration of lymphocyte mediators. J Clin Invest (1974) 1.21
IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest (1976) 1.17
The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest (1976) 1.09
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest (1997) 1.03
Basophil histamine release in patients with hay fever. Results compared with specific IgE and total IgE during immunotherapy. Clin Exp Immunol (1977) 0.99
Influence of degree of specific allergic sensitivity on severity of rhinitis and asthma in Chinese allergic patients. Respir Res (2011) 0.97
Immunotherapy in respiratory allergy. Thorax (1983) 0.92
Influence of IgG antibody and glycopeptide allergens on the correlation between the radioallergosorbent test (RAST) and skin testing or bronchial challenge with alternaria. Clin Exp Immunol (1975) 0.91
The quantification of IgE antibody specific for ragweed Antigen E (AgE) on the basophil surface in patients with ragweed pollenosis. Immunology (1978) 0.89
Influence of hyposensitization of ATP level and CO2 production of mast cells in anaphylaxis. Clin Exp Immunol (1976) 0.88
Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child (2004) 0.85
IgE epitope proximity determines immune complex shape and effector cell activation capacity. J Allergy Clin Immunol (2015) 0.85
Assessing basophil functional measures during monoclonal anti-IgE therapy. J Immunol Methods (2012) 0.84
Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest (1990) 0.83
Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy. J Allergy Clin Immunol (2015) 0.83
Quantitative relationships between IgE antibody and blocking antibodies specific for antigen E in patients given immunotherapy with ragweed antigen E. Clin Exp Immunol (1977) 0.81
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
The radioallergosorbent test: a method to measure IgE antibodies, IgG blocking antibodies, and the potency of allergy extracts. Bull N Y Acad Med (1981) 0.77
Determination of immunological stress and oxygen free radical formation in white blood cells during allergen immunotherapy. Med Sci Monit (2012) 0.77
Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76
Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2015) 0.76
The rationale for immunotherapy in respiratory allergies. Trans Am Clin Climatol Assoc (1978) 0.75
New insights into the mechanisms of immunotherapy. Eur Arch Otorhinolaryngol (1995) 0.75
A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther (1959) 16.61
Chemical coupling of proteins to agarose. Nature (1967) 10.52
STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN. J Exp Med (1964) 6.30
Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet (1967) 6.12
A new class of immunoglobulin in human serum. Immunology (1968) 4.19
General methods for the study of cells and serum during the immune response: the response to dinitrophenyl in mice. Clin Exp Immunol (1969) 4.00
Immunological studies of an atypical (myeloma) immunoglobulin. Immunology (1967) 3.52
Measurement of IgE in normal and allergic serum by radioimmunoassay. J Lab Clin Med (1971) 3.47
Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol (1967) 3.05
Immunoglobulin levels in Ethiopian preschool children with special reference to high concentrations of immunoglobulin E (IgND). Lancet (1968) 2.72
Isolation studies of allergens from regweed pollen. Biochemistry (1962) 2.04
Procedures for immunochemical study of histamine release from leukocytes with small volume of blood. J Allergy (1970) 1.87
Clinical aspects of IgE myeloma. N Engl J Med (1969) 1.85
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Studies on the mechanisms of hypersensitivity phenomena. XIV. Passive sensitization in vitro of human leukocytes to ragweed pollen antigen. J Immunol (1966) 1.75
Radioimmunoassays employing immunosorbents. Acta Endocrinol Suppl (Copenh) (1969) 1.74
In vitro diagnosis of atopic allergy. I. A comparison between provocation tests and the radioallergosorbent test. Int Arch Allergy Appl Immunol (1971) 1.60
Regulation of homocytotropic antibody formation in the rat. I. Feed-back regulation by passively administered antibody. J Immunol (1971) 1.55
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
SUPPRESSION OF HAY FEVER SYMPTOMS WITH INTRANASAL DEXAMETHASONE AEROSOL. J Allergy (1965) 1.44
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42
In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. J Clin Invest (1966) 1.29
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol (1968) 1.28
A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med (1971) 1.27
Serum IgND levels in healthy children and adults. Int Arch Allergy Appl Immunol (1968) 1.26
Behaviour of mouse mast cells during anaphylaxis in vitro. Prog Allergy (1969) 1.18
Antigenic structure of gamma-E-globulin and reaginic antibody. J Immunol (1967) 1.15
Studies on the mechanisms of hypersensitivity phenomena. XII. An in vitro study of the reaction between ragweed pollen antigen, allergic human serum and ragweed-sensitive human leukocytes. J Immunol (1966) 1.12
In vitro diagnosis of atopic allergy. 3. Quantitative estimation of circulating IgE antibodies by the radioallergosorbent test. Int Arch Allergy Appl Immunol (1971) 1.06
Reaginic antibody formation in the mouse. I. Antibody-mediated suppression of reaginic antibody formation. J Immunol (1972) 1.04
Studies on the mechanisms of hypersensitivity phenomena. XVI. In vitro assays of reaginic activity in human sera: effect of therapeutic immunization on seasonal titer changes. J Immunol (1967) 1.02
Histamine release from leukocytes of hypersensitive individuals. II. Reduced sensitivity of leukocytes after injection therapy. J Allergy (1967) 0.91
In vitro diagnosis of atopic allergy. II. IgE and reaginic antibodies during and after rush desensitization. Int Arch Allergy Appl Immunol (1971) 0.88
Some factors influencing the serum IgE levels in atopic diseases. Clin Exp Immunol (1970) 0.87
Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol (1972) 0.86
In vitro assay of allergenic properties of ragweed pollen antigens. J Allergy (1966) 0.82
Activation of the alternate pathway of human complements by rabbit cells. J Immunol (1974) 5.59
Magnetic control of ferroelectric polarization. Nature (2003) 5.23
Ragweed immunotherapy in adult asthma. N Engl J Med (1996) 4.69
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes. J Immunol (1967) 3.37
Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol (1967) 3.05
Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody. J Immunol (1966) 2.92
Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol (1970) 2.91
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
Distribution of gamma E-forming cells in lymphoid tissues of the human and monkey. J Immunol (1970) 2.66
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol (1966) 2.62
Regulation of IgE synthesis. Annu Rev Immunol (1984) 2.61
Anaphylaxis. N Engl J Med (1991) 2.53
Stimulation of phospholipid methylation, Ca2+ influx, and histamine release by bridging of IgE receptors on rat mast cells. Proc Natl Acad Sci U S A (1980) 2.50
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
Regulation of antibody response in vitro. VI. Carrier-specific helper cells for IgG and IgE antibody response. J Immunol (1973) 2.33
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Biologic function of the Fc fragments of E myeloma protein. Immunochemistry (1970) 2.23
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 2.22
Lymphocytes bearing Fc receptors for IgE. I. Presence of human and rat T lymphocytes with Fc epsilon receptors. J Immunol (1979) 2.20
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
Generation of specific helper cells and suppressor cells in vitro for the IgE and IgG antibody responses. J Immunol (1976) 2.18
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Cellular events in the IgE antibody response. Adv Immunol (1976) 2.16
Biology of immunoglobulin E. Molecular basis of reaginic hypersensitivity. Prog Allergy (1975) 2.15
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
A research standard for human serum immunoglobulin E. Bull World Health Organ (1970) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Activation of mast cells for mediator release through IgE receptors. Prog Allergy (1984) 2.01
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Genetic control of basal serum immunoglobulin E level and its effect on specific reaginic sensitivity. Proc Natl Acad Sci U S A (1974) 1.98
Proteolytic degradation of exocrine and serum immunoglobulins. J Clin Invest (1970) 1.97
IgA and IgA diphtheria antitoxin responses from human tonsil lymphocytes. J Immunol (1975) 1.97
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Mechanisms of passive sensitization. 3. Number of IgE molecules and their receptor sites on human basophil granulocytes. J Immunol (1973) 1.87
Clinical aspects of IgE myeloma. N Engl J Med (1969) 1.85
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Histamine release from human leukocytes by anti-gamma E antibodies. J Immunol (1969) 1.84
Triggering of histamine release from rat mast cells by divalent antibodies against IgE-receptors. J Immunol (1978) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. J Immunol (1966) 1.80
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
Reversed type allergic skin reactions by anti-gamma-E-globulin antibodies in humans and monkeys. J Immunol (1968) 1.75
Development of rat mast cells in vitro. I. Differentiation of mast cells from thymus cells. J Immunol (1976) 1.74
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
Immunochemical properties of human gamma-A isohemagglutinin. I. Comparisons with gamma-G and gamma-M-globulin antibodies. J Immunol (1965) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
Mechanisms of passive sensitization. IV. Dissociation of IgE molecules from basophil receptors at acid pH. J Immunol (1974) 1.62
Immune mechanisms of reversed type reaginic hypersensitivity. J Immunol (1969) 1.61
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Direct demonstration of increased intracellular concentration of free calcium as measured by quin-2 in stimulated rat peritoneal mast cell. Proc Natl Acad Sci U S A (1984) 1.58
Presence of gammaE in nasal washings and sputum from asthmatic patients. J Allergy (1970) 1.56
Biological function of gamma E antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol (1970) 1.56
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Human reaginic antibodies and immunoglobulin E. J Allergy (1968) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Formation of IgE binding factors by human T lymphocytes. J Immunol (1981) 1.53
Mechanisms of reaginic hypersensitivity and IgE antibody response. Immunol Rev (1978) 1.52
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Immunoglobulin switch circular DNA in the mouse infected with Nippostrongylus brasiliensis: evidence for successive class switching from mu to epsilon via gamma 1. Proc Natl Acad Sci U S A (1990) 1.49
Development of mast cells in vitro. II. Biologic function of cultured mast cells. J Immunol (1977) 1.48
Surface IgE on human basophils during histamine release. J Exp Med (1973) 1.48
The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J Immunol (1970) 1.48
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48